secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acurx Pharmaceuticals, Inc. (ACXP)
CIK:        0001736243
Form:       8-K
Filed at:   2023-03-16T23:59:59+00:00
Accession:  0001104659-23-033054
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acurx reports Q4/FY2022 net loss; Phase 2b CDI trial interim IDMC review at 36 patients
--------------------------------------------------------------------------------

- Cash $9.1M at Dec 31, 2022 vs $13.0M a year earlier.
- Q4 net loss $3.3M ($0.28/share) vs $2.6M ($0.26); FY net loss $12.1M ($1.12) vs $12.7M ($1.49).
- R&D expense FY2022 $4.8M (up from $2.0M) due to Phase 2b costs; G&A $7.3M (down from $10.8M).
- Phase 2b CDI trial has enrolled 25 of 36 patients needed for IDMC interim review; IDMC may recommend early termination or continue enrollment.
- Non-dilutive grant application for $11.3M for ACX-375 (MRSA) in final round; decision expected in April 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1736243/000110465923033054/0001104659-23-033054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1736243/000110465923033054/tm239317-2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-033054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer